A phase II, randomized, double-blind, placebo-controlled bronchoscopy study to evaluate the effects of lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhaled corticosteroids and a second controller medication
Highlights of Past Studies
A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
Steroids in Eosinophil Negative Asthma
A Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab
Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Severe COPD
Long-Acting Beta Agonist Step Down Study
A number of studies have suggested that sleep-disordered breathing, including obstructive sleep apnea, increases the risk of high blood pressure, heart attack, and stroke. But so far, no studies have quantified that risk over time.
The Tucson Epidemiological Study of Airway Obstructive Disease is a population-based prospective cohort study initiated in 1972 in Tucson, Arizona. At study initiation, 3,805 Tucson residents between the ages of 6 to 95 years participated.